NCT00263874 - Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD | Biotech Hunter

Enrollment

324

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

September 30, 2006

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

UK-500,001

Trial Locations (28)

1426

Pfizer Investigational Site, Buenos Aires

1602

Pfizer Investigational Site, Vicente López

2000

Pfizer Investigational Site, Rosario

2045

Pfizer Investigational Site, Törökbálint

2050

Pfizer Investigational Site, Camperdown

4004

Pfizer Investigational Site, Debrecen

6009

Pfizer Investigational Site, Nedlands

8200

Pfizer Investigational Site, Veszprém

10000

Pfizer Investigational Site, Zagreb

28007

Pfizer Investigational Site, Madrid

28046

Pfizer Investigational Site, Madrid

308433

Pfizer Investigational Site, Singapore

529889

Pfizer Investigational Site, Singapore

2381594

Pfizer Investigational Site, ValparaÃ-so

7500691

Pfizer Investigational Site, Santiago

Pfizer Investigational Site, Providencia

C1904AGP

Pfizer Investigational Site, La Plata

C1425DQU

Pfizer Investigational Site, Buenos Aires

3168a

Pfizer Investigational Site, Clayton

T1Y 6J4

Pfizer Investigational Site, Calgary

T4N 6V7

Pfizer Investigational Site, Red Deer

L8N 3Z5

Pfizer Investigational Site, Hamilton

K7L 2V7

Pfizer Investigational Site, Kingston

775 20

Pfizer Investigational Site, Olomouc

708 52

Pfizer Investigational Site, Ostrava-Poruba

150 06

Pfizer Investigational Site, Prague

390 03

Pfizer Investigational Site, Tábor

M23 9LT

Pfizer Investigational Site, Manchester